MTS Securities Advises Iroko Pharmaceuticals on $75MM Facility
Iroko Pharmaceuticals announced it entered into a $75 million facility with an OrbiMed Advisors affiliate to support operations and its ZORVOLEX™ launch. MTS Securities acted as financial advisor.
November 22, 2013
Iroko Pharmaceuticals | OrbiMed Advisors
ABF Journal